The Egyptian Pressure: How Cairo Criminalised the World's Medicine at Geneva in 1925: What Modern Science Says About Every Claim Made That Afternoon
On 19 February 1925, one man walked into the Salle de la Réformation in Geneva and made five claims about cannabis. Those five claims, unsupported by scientific citation, unreviewed against existing evidence, and driven by economic interests he did not disclose, became the legal foundation for a century of global prohibition. One hundred and one years later, The Meridian places each claim before the full weight of modern science, neuroscience, economics, and the League of Nations' own archives. The verdict is damning. Not of cannabis. Of the speech that banned it.
Dr Mohamed Abdel Salam El Guindy attended the Second International Opium Conference of the League of Nations as the delegate for the Egyptian Government and the Secretary of the Royal Legation of Egypt in Paris and Brussels. Cannabis was not on the conference agenda. The conference had been convened to set limits on the legal production of morphine, heroin, and cocaine. El Guindy changed that. He presented what he described as a carefully prepared address proposing that cannabis be treated as a habit-forming drug subject to the same strict international controls as opium. The conference heard him. Turkey and the United States supported his proposal. Britain initially opposed it, not for scientific reasons, but because of hemp's industrial value and the lucrative colonial trade with India. The coalition for prohibition prevailed. Cannabis was added to the convention. The Indian delegation's formal objection, grounded in the 1894 Hemp Drugs Commission's findings, in three thousand years of Vedic tradition, and in the lived reality of a subcontinent that had used this plant as medicine and sacrament since the Atharva Veda, was formally recorded and formally overridden. What El Guindy said that afternoon is now public record. What modern science says about what he said is the subject of this article.
El Guindy five claims cannabis 1925 Geneva modern science verdict neuroscience economics history
El Guindy made five documented claims in his address to the Second Opium Conference. Each is reproduced here verbatim from the conference proceedings as documented in the historical record. Each is then assessed against the full body of scientific evidence available in 2026. The sources for each scientific assessment are named and verifiable. The reader is invited to check every one of them.
"Small doses caused agreeable inebriation and a desire to smile, stronger doses led to a feeling of oppression, discomfort, and hilarious and noisy delirium. Large doses produced furious delirium, physical agitation, and a subsequent state of stupor."
The dose-response curve El Guindy described is broadly accurate and is now explained by the neuropharmacology of the endocannabinoid system. At low doses, THC activates CB1 receptors in the brain's reward pathways, producing the mild euphoria and sociability El Guindy described as "agreeable inebriation." At higher doses, particularly with high-potency resin such as hashish, THC can disrupt the balance of dopamine, GABA, and glutamate neurotransmission, producing the anxiety, discomfort, and perceptual disturbance El Guindy described. At very high doses, acute psychosis-like symptoms (the "furious delirium") can occur, followed by sedation.
What El Guindy described as a moral catastrophe, modern neuroscience recognises as a dose-dependent pharmacological response that is self-limiting, temporary, and produces no lasting neurological damage in adults with no genetic predisposition to psychosis. No human being has ever died from cannabis overdose at any dose. The same dose-response curve he described applies to alcohol, paracetamol, and aspirin, all of which remain legal.
Sources: Bhattacharyya S et al., "Differential Effects of CBD and THC on Brain Activity." Neuropsychopharmacology, 2010. Mechoulam R, Parker L, "The Endocannabinoid System and the Brain." Annual Review of Psychology, 2013. Grotenhermen F, "Pharmacokinetics and Pharmacodynamics of Cannabinoids." Clinical Pharmacokinetics, 2003.
"Cannabis use caused physical decay and weakened intellectual faculties."
"Physical decay" is not supported by any peer-reviewed literature on cannabis. The Indian Hemp Drugs Commission of 1894, which studied cannabis users across the Indian subcontinent for two years, found no evidence of physical deterioration attributable to moderate cannabis use. More than a century of subsequent research has confirmed this. Cannabis does not cause organ failure. It does not cause progressive physical disease. It does not cause death. The World Health Organisation's 2019 review of cannabis, the most comprehensive international scientific assessment ever conducted, found no evidence that cannabis use causes physical deterioration in adults.
The claim about intellectual faculties is more nuanced. Heavy cannabis use beginning in adolescence, before the brain's prefrontal cortex has fully developed, is associated with modest reductions in certain cognitive measures in some studies. This is a real risk for adolescent users and a legitimate public health argument for age-restricted regulation: precisely the regulatory framework that Canada, Germany, and 24 American states have implemented. It is not an argument for blanket criminal prohibition of adults, which is what the 1925 Convention established.
Sources: WHO Expert Committee on Drug Dependence, Critical Review of Cannabis, 2019. Available at: who.int. Indian Hemp Drugs Commission Report, 1894–1895, Government of India. Meier MH et al., "Persistent cannabis users show neuropsychological decline." PNAS, 2012. Rogeberg O, "Correlations Between Cannabis Use and IQ Change." PNAS, 2013 (methodological critique of Meier).
"Cannabis use frequently led to neurasthenia and insanity. The illicit use of hashish is the principal cause of most insanity cases in Egypt."
This is the most consequential claim El Guindy made, and it is the one that modern science has examined most thoroughly. The verdict is precise: he was not entirely wrong about the association, but he was catastrophically wrong about the causation, the scale, and the conclusion he drew.
Modern epidemiological research confirms that heavy, frequent use of high-potency cannabis is associated with an increased risk of psychosis and schizophrenia in individuals with a genetic predisposition. A landmark 2019 study published in The Lancet Psychiatry found that daily use of high-potency cannabis was associated with a fivefold increase in the odds of psychosis compared with non-use. This is a real finding. El Guindy was observing something real in the heaviest hashish users in Egypt.
But his conclusion, that cannabis is "the principal cause of most insanity cases", is demolished by one decisive data point. Global cannabis use has increased exponentially since 1925. If El Guindy were right, global rates of schizophrenia and psychosis would have increased in direct proportion. They have not. The rate of schizophrenia has remained flat at approximately 1 percent of the global population for the entirety of the period during which cannabis use expanded from a minority practice to a mainstream global behaviour. This is what epidemiologists call the "null ecological finding": the absence of a population-level effect where one would be expected if the causal claim were true.
The modern scientific consensus, as stated by the WHO in 2019, is that cannabis is a component cause of psychosis in genetically predisposed individuals, not the principal cause of most insanity cases. El Guindy's claim was hyperbolic by a factor of several orders of magnitude, and its legal consequences, namely 101 years of global prohibition, were built on that hyperbole.
Sources: Di Forti M et al., "The contribution of cannabis use to variation in the incidence of psychotic disorder." The Lancet Psychiatry, 2019. doi:10.1016/S2215-0366(19)30048-3. Gage SH, Hickman M, Zammit S, "Association Between Cannabis and Psychosis." Biological Psychiatry, 2016. Murray RM et al., "Cannabis-associated psychosis: Neural substrate and clinical significance." Neuropharmacology, 2017. WHO Expert Committee on Drug Dependence, Critical Review of Cannabis, 2019.
"If left unchecked in the absence of opium, cannabis would become a terrible menace to the whole world."
One hundred and one years have elapsed since El Guindy made this warning. The record is now complete enough to assess it directly. Canada legalised cannabis for adult recreational use in 2018. Germany legalised it in April 2024. Uruguay, Malta, Luxembourg, Thailand, and twenty-four American states have done the same. South Africa's Constitutional Court ruled in 2018 that private cultivation and use is a constitutional right. Lesotho, Zimbabwe, Malawi, Zambia, Ghana, and Morocco have legalised medical cultivation. The global legal cannabis market was valued at $57 billion in 2023 and is projected to reach $100 billion by 2028.
The "terrible menace to the whole world" that El Guindy warned of has not materialised in any jurisdiction that has legalised cannabis. In Canada, youth cannabis use rates have remained stable or declined since legalisation. In Colorado, the first American state to legalise adult recreational use in 2012, cannabis-related road deaths have not increased above the statistical trend. In the Netherlands, where cannabis has been available in regulated coffee shops since the 1970s, the rate of cannabis use is lower than in the United Kingdom, where it remains illegal. El Guindy's prediction is not merely unverified. It is empirically contradicted by the documented outcomes in every major jurisdiction that has ended prohibition.
Sources: Health Canada, Cannabis Legalization and Regulation, National Cannabis Survey 2023. health.canada.ca. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Cannabis Policy Report, 2024. emcdda.europa.eu. RAND Drug Policy Research Center, "Legalizing Marijuana in Colorado." 2013. Decorte T et al., "European Cannabis Policies and Their Apparent Impact." International Journal of Drug Policy, 2022.
"Cannabis should be treated as a habit-forming drug subject to the same strict international controls as opium."
This was El Guindy's operational conclusion: the legal proposal that emerged from his four preceding claims. It is assessed here not on its claims but on its consequences against the available evidence on addiction liability. The WHO's standard measure of addiction potential for psychoactive substances is the proportion of users who develop clinical dependence. For cannabis, that figure is 9 percent. For alcohol: 15 percent. For cocaine: 17 percent. For heroin: 23 percent. For tobacco: 32 percent. Cannabis has the lowest addiction liability of any commonly used psychoactive substance, legal or illegal. Opium derivatives, the substances whose control regime El Guindy proposed extending to cannabis, have an addiction liability of 23 percent for heroin and produce a documented physical withdrawal syndrome that can be fatal. Cannabis produces no physical withdrawal syndrome comparable in severity to alcohol or opioids. No human being has died from cannabis withdrawal. The claim that cannabis should be subject to the same controls as opium is not supported by any scientific comparison of their pharmacological profiles.
Sources: Anthony JC, Warner LA, Kessler RC, "Comparative Epidemiology of Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants." Experimental and Clinical Psychopharmacology, 1994. WHO Expert Committee on Drug Dependence, Critical Review of Cannabis, 2019. Lopez-Quintero C et al., "Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine." Drug and Alcohol Dependence, 2011.
Egypt cotton economic interest cannabis prohibition 1925 labour force control fellahin hemp competition trade protectionism
El Guindy's five claims are the public record of the 1925 Geneva conference. What he did not say is the private record of Egyptian economic interest, and it is, in some respects, more damning than what he said.
Egypt in 1925 was the world's pre-eminent producer of long-staple cotton, the raw material for the finest textiles and a primary engine of the Egyptian colonial economy. The agricultural system that produced that cotton depended on the labour of the Egyptian fellahin, the rural peasantry, who worked the cotton fields under conditions of state-coerced agricultural labour. Cannabis, specifically hashish, was cheap and widely available, and consumed throughout Egyptian society and particularly in the working-class bazaars and rural communities that constituted the cotton labour force.
When El Guindy warned that cannabis caused "physical decay" and "weakened intellectual faculties," he was doing something beyond making a pharmacological claim. He was articulating the anxiety of a ruling class whose primary economic asset was the productive physical capacity of its workforce. A fellahin worker sedated by hashish was, from the perspective of the cotton estate owner, a less exploitable unit of labour. The prohibition of cannabis in Egypt, and the international prohibition El Guindy sought, was as much a labour discipline mechanism as a public health initiative. The British colonial government in Mauritius had made the identical calculation in 1840, when it banned gandia among the indentured sugar estate workers on the explicit grounds that it was being used "to excess among the labouring class."
Hemp, the industrial variety of the cannabis plant, was also a direct competitor to cotton in fibre and textile markets. An international prohibition that restricted cannabis cultivation globally would reduce competition for Egyptian long-staple cotton in international fibre markets. El Guindy did not disclose this commercial alignment to the Geneva delegates. The League of Nations archives do not record any delegate raising it. The conflict of interest was structural and it was not mentioned.
The prohibition of cannabis in Egypt was as much a labour discipline mechanism as a public health initiative. The British colonial government in Mauritius had made the identical calculation in 1840.
India 1925 Geneva cannabis objection hemp drugs commission 1894 religious cultural use British colonial delegation overruled
The Indian delegation to the Second Opium Conference raised a formal objection to El Guindy's proposal. The objection was grounded in four arguments, all of which were documented, verifiable, and scientifically sound. All four were overruled.
First, the delegation pointed to the Indian Hemp Drugs Commission Report of 1894 to 1895, comprising seven volumes, 1,193 witnesses, and three years of study, the most comprehensive scientific investigation of cannabis ever conducted by any government, which had concluded that moderate use caused no significant harm and that prohibition would be unjust and counterproductive. The Commission's findings were available, published, and in the record. El Guindy had not cited them. The conference did not require him to.
Second, the delegation noted that cannabis grew wild across the Indian subcontinent and was so deeply embedded in social and religious life, encompassing the bhang tradition, the Shiva connection, and the Holi and Mahashivaratri festivals, such that total prohibition would be administratively impossible to enforce and would constitute a direct assault on religious freedom of ancient and legitimate standing.
Third, the British colonial government in India controlled a heavily taxed, legally regulated domestic market for cannabis products including bhang and ganja that represented a significant source of state revenue. The 1925 Convention as proposed by El Guindy would have destroyed this revenue base.
The resulting compromise reflected the power dynamics of the room rather than the weight of the evidence. The conference voted to add cannabis to the convention's controls but included a limited exemption for bhang leaves used in Indian religious practice. Ganja and charas, the therapeutically most significant preparations, were controlled without exemption. The Indian delegation's scientific arguments were formally noted. They were not formally answered. A scientific objection grounded in three thousand years of documented use and the most comprehensive government study of cannabis ever conducted was overridden by a speech that cited no scientific sources at all.
The conference: Second International Opium Conference, Geneva, 17 November 1924 to 19 February 1925. Forty nations represented. League of Nations Official Documents Series. Archives held at the United Nations Office at Geneva, Palais des Nations.
The proposal: El Guindy proposed on 19 February 1925 that Indian hemp be added to the substances controlled under the convention. This is documented in the conference proceedings: Records of the Second International Opium Conference, C.760.M.260.1924.XI, League of Nations.
Who supported it: Turkey and the United States immediately. South Africa subsequently. Britain initially opposed due to industrial hemp value and Indian trade.
Who opposed it: The Indian delegation formally objected. The Dutch delegation raised concerns about enforcement. Both objections were overridden.
The result: Article 11 of the 1925 International Opium Convention extended controls to Indian hemp, requiring signatory nations to limit export to countries that prohibited its importation. First inclusion of cannabis in an international drug control treaty.
What was not cited: The Indian Hemp Drugs Commission Report, 1894-1895. The Ayurvedic medical literature. The Atharva Veda. Any peer-reviewed scientific study of cannabis pharmacology. None of these were entered into the conference record as evidence for or against El Guindy's proposal.
endocannabinoid system cannabis mechanism El Guindy description retrograde signal GABA glutamate therapeutic accidental
There is one dimension of El Guindy's speech that deserves a different kind of attention. When he described cannabis producing a "furious delirium" in large doses followed by a "state of stupor," he was, without knowing it, describing the action of the endocannabinoid system on the brain's primary neurotransmitters. The "furious delirium" is the acute disruption of the balance between glutamate (the brain's excitatory neurotransmitter) and GABA (the brain's inhibitory neurotransmitter). The "stupor" is the subsequent compensatory sedation as the system rebalances.
The endocannabinoid system was not discovered until 1988, sixty-three years after El Guindy spoke. The mechanism by which cannabis interacts with CB1 receptors to modulate GABA and glutamate was not understood until Raphael Mechoulam's decades of work following his isolation of THC in 1964. But the same mechanism El Guindy described in extreme and alarming terms, the modulation of the brain's excitatory and inhibitory balance, is precisely the mechanism by which cannabis treats epilepsy (by reducing glutamate-driven seizure activity), PTSD (by interrupting the over-activated fear loop), and chronic pain (by modulating pain signal transmission). El Guindy described the therapeutic mechanism of a medicine and concluded it was a menace. The science spent the following century proving him exactly backwards.
cannabis 101 years prohibition verdict El Guindy 1925 Geneva modern science evidence Mauritius Dangerous Drugs Act 2000
The chain from the Salle de la Réformation in Geneva on 19 February 1925 to the Grade 6 classroom in southern Mauritius on 27 May 2026 is documented, direct, and unbroken. El Guindy's five claims, partially accurate on dose-response, wrong on physical decay, hyperbolic on insanity, empirically false on global menace, and pharmacologically baseless on equivalence with opium, became the diplomatic foundation for the 1961 UN Single Convention, which placed cannabis in Schedule IV alongside heroin, which bound every signatory state including Mauritius, which produced the Dangerous Drugs Act 2000, which governs the life of every Mauritian citizen who uses a plant that the human body was designed to receive.
The reader who wishes to verify every claim in this article will find every source named and cited. The WHO Critical Review of Cannabis is publicly available at who.int. The Lancet Psychiatry study by Di Forti et al. carries the DOI 10.1016/S2215-0366(19)30048-3. The Indian Hemp Drugs Commission Report is digitised at archive.org. The League of Nations conference proceedings are held at the United Nations Office at Geneva. The Anthony et al. addiction liability study is cited in every pharmacology textbook published since 1994. The evidence has been available. The law has not followed it. That is not an accident. That is a decision. And decisions can be changed.
El Guindy described the therapeutic mechanism of a medicine and concluded it was a menace. The science spent the following century proving him exactly backwards.
This is the third article in Chapter One of The Colonised Plant: The Cannabis Edition, June 2026. Chapter Two, The Science, opens with Dr Raphael Mechoulam, the Israeli chemist who spent sixty years proving what El Guindy got wrong. The complete edition is published at themeridian.info/june-2026.
Add comment
Comments